There has been a dearth of evidence-based screening guidelines for women age < 40 with a family history of breast cancer, a BRCA1 or BRCA2 mutation, or other risk factors, largely because of the lack of randomized, controlled trials to inform the development of such guidelines [48-50]. Here, BRCA2 is linked to breast cancer.